查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918336

医药级乳糖市场－2026-2031年预测

Pharmaceutical Grade Lactose Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计药用级乳糖市场将从 2025 年的 20.06 亿美元成长到 2031 年的 27.52 亿美元，复合年增长率为 5.41%。

全球药用级乳糖市场是一个主要源自于乳酪生产的专业细分市场，其产品符合严格的医药应用品质标准。这种高纯度乳糖主要用作赋形剂，惰性物质，可作为活性药物成分 (API) 的载体，改善製剂的流动性、可压性、稳定性和口感。其主要应用包括片剂和胶囊剂的生产、干粉吸入剂 (DPI)、口服液，以及作为注射剂和吸入剂的稀释剂或填充剂。此外，药用级乳糖也为婴幼儿奶粉提供必需的碳水化合物和能源来源，支持婴幼儿的早期营养和发育。人们对乳糖在儿童营养和药物疗效方面的益处的认识不断提高，加上全球医疗保健支出的成长，正在推动市场扩张。人口老化和慢性病发病率的上升进一步刺激了市场需求，乳糖有助于生产常用的口服固体製剂常用于治疗癌症、糖尿病、心血管疾病和其他疾病。

关键市场驱动因素反映了医疗保健结构的趋势：对製药业的投资不断增长，尤其是在印度和巴西等新兴经济体，这提高了学名药和慢性病新治疗方法的生产能力，直接推动了对辅料的需求。

慢性疾病发生率不断上升，尤其是预计未来 20 年新增癌症病例将增加 70%，这推动了抗癌药物的需求，而乳糖是这些药物的关键稀释剂和填充剂。

药用级乳糖用途广泛，已成为各种配方中多种应用的首选辅料，包括控制释放、掩味、提高原料药稳定性以及提高溶解度和生物利用度。

随着全球人口老化加剧，治疗与老龄化相关的慢性疾病的药物需求不断增长，而乳糖是製造常见药片和胶囊的重要成分。

从细分市场来看，α-乳糖一水合物类别预计将主导市场并实现显着增长，因为与其他乳糖变体相比，它具有更优异的延长保质期特性，因此被广泛用作固态剂型和干粉吸入剂 (DPI) 中的填充剂、稀释剂和载体。

按地区划分，预计北美将继续保持显着的市场份额和健康的复合年增长率。该地区的主导地位归功于主要生产商和供应商的集中，以及全球製药领导者美国製药业的强劲成长。乳糖作为片剂、胶囊、口服液和吸入粉剂辅料的日益普及也支撑了市场需求。此外，人们普遍认为乳糖配方奶粉有益于消化器官系统，并能减少婴儿胃肠道疾病，加上家长和专业人士对此意识提升，也推动了奶粉的普及。

重点产品具有特殊的性能特性。

Armor Protein 的 ArmorPharma™ 乳糖一水合物 200M 是一种精细研磨的 α-乳糖一水合物粉末，针对片剂生产中的湿法和干法製粒进行了优化，具有优异的混合和压片性能。

Charotar Casein 公司生产的「乳糖製药」经过严格的品管，精心加工，达到低水分（5.10%）和低酸度（0.20），确保高纯度、透明度和有效性。

BASF的Rudypress®是一种共加工颗粒，由一水乳糖（93%）、Kollidon® 30（3.5%）和Kollidon® CL（3.5%）製成。这种白色、流动性好、无味的物质简化了片剂生产过程，并能生产出硬度高、不易碎的片剂，这些片剂能够快速崩坏并释放活性成分。

药用级乳糖市场受益于多种因素的共同推动，包括慢性病发病率上升、人口老化、乳糖作为辅料的多功能性以及製药业的投资。北美的製造生态系统和製剂应用巩固了该地区的地位，而α-乳糖一水合物的功能优势则使其在该领域占据主导地位。随着全球医疗费用支出不断增长，以及人们对乳糖在药物输送和婴幼儿营养中的作用认识不断提高，该领域为专注于纯度合规、定制和应用创新的供应商提供了持续的机会。业内相关人员应密切关注监管政策的变化和新兴的治疗方法，以优化其在这个蓬勃发展的辅料领域的市场定位。

本报告的主要优势：

  • 深入分析：获得主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要企业的策略倡议，并了解透过正确的策略进入市场的可能性。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

企业使用我们的报告的目的是什么？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯）及主要发展动态。

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 依产品类型分類的药用级乳糖市场

  • 介绍
  • β-乳糖
  • α-乳糖一水合物
  • 无定形乳糖
  • 喷雾干燥乳糖

6. 依应用分類的药用级乳糖市场

  • 介绍
  • 药片
  • 胶囊
  • 干粉吸入器（DPI）
  • 小袋
  • 注射剂（填充剂）
  • 口服悬浮液

7. 以最终用户分類的医药级乳糖市场

  • 介绍
  • 製药公司
  • 契约製造组织（CMO）
  • 合约研发生产组织（CDMO）
  • 营养补充品製造商
  • 研究与开发实验室

8. 按地区分類的药用级乳糖市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 台湾
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Armor Proteines（Savencia Group）
  • BASF Corporation
  • Charotar Casein Company
  • Fengchen Group Co., Ltd.
  • Alpavit
  • Kavya Pharma
  • Lactose（India）Limited
  • MEGGLE GmbH & Co. KG
  • FrieslandCampina
  • Surfachem Group Ltd.（2M Holdings）.

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061616350

Pharmaceutical Grade Lactose Market is projected to increase at a 5.41% CAGR, growing from USD 2.006 billion in 2025 to USD 2.752 billion in 2031.

The global pharmaceutical-grade lactose market represents a specialized segment derived primarily from cheese production byproducts, adhering to rigorous quality standards for pharmaceutical applications. This high-purity lactose functions predominantly as an excipient-an inert substance serving as a vehicle for active pharmaceutical ingredients (APIs)-enhancing flowability, compressibility, stability, and taste in formulations. Key uses include tablet and capsule production, dry powder inhalers (DPIs), oral solutions, and as a diluent or filler in injectable and inhalable drugs. Additionally, pharmaceutical-grade lactose provides essential carbohydrates and energy in infant formulas, supporting early childhood nutrition and development. Rising awareness of its benefits in pediatric nutrition and pharmaceutical efficacy, coupled with escalating global healthcare expenditures, is propelling market expansion. The aging population and increasing prevalence of chronic diseases further amplify demand, as lactose facilitates oral solid dosage forms commonly prescribed for conditions like cancer, diabetes, and cardiovascular disorders.

Primary market drivers underscore structural healthcare trends. Growing investments in pharmaceutical manufacturing, particularly in emerging economies like India and Brazil, bolster production capacities for generics and novel therapies targeting chronic illnesses, directly elevating excipient requirements.

Rising chronic disease incidence, notably cancer-projected for a 70% increase in new cases over the next two decades-heightens demand for anticancer medications where lactose serves as a critical diluent and filler.

The versatility of pharmaceutical-grade lactose across applications-drug release modification, flavor masking, API stability enhancement, and improved solubility/bioavailability-positions it as a preferred excipient in diverse formulations.

Demographic shifts toward an older global population drive medication needs for age-related chronic conditions, with lactose integral to prevalent tablet and capsule formats.

From a segmentation perspective, the a-lactose monohydrate category is anticipated to dominate and exhibit substantial growth. Its widespread adoption as a filler, diluent, and carrier in solid dosage forms and DPIs stems from superior shelf-life extension compared to other lactose variants.

Geographically, North America is projected to maintain a significant market share and healthy CAGR. The region's leadership arises from a concentration of major producers and suppliers, alongside robust pharmaceutical industry growth in the United States-a leading global market for drug products. Increasing incorporation of lactose as an excipient in tablets, capsules, oral solutions, and inhalation powders supports demand. Furthermore, recognition of lactose-based infant formulas' digestive benefits and reduced gastrointestinal issues in infants is fostering formula uptake amid heightened parental and professional awareness.

Leading product offerings highlight specialized performance characteristics.

ARMOR PROTEINS' ARMOR PHARMA(TM) lactose monohydrate 200M is a finely milled a-lactose monohydrate powder optimized for wet and dry granulation in tablet production, delivering excellent mixing and compaction properties.

Charotar Casein Company's Lactose pharma undergoes meticulous processing to achieve low moisture (5.10%) and acidity (0.20), ensuring high purity, clarity, and efficacy under stringent quality controls.

BASF Corporation's Ludipress(R) is a co-processed granulate comprising lactose monohydrate (93%), Kollidon(R) 30 (3.5%), and Kollidon(R) CL (3.5%). This white, free-flowing, tasteless material simplifies tableting, yielding hard, low-friability tablets with rapid disintegration and API release.

The pharmaceutical-grade lactose market is underpinned by converging factors: chronic disease proliferation, geriatric demographics, excipient versatility, and pharmaceutical sector investments. North America's manufacturing ecosystem and formulation adoption reinforce its prominence, while a-lactose monohydrate's functional superiority drives segmental leadership. As global healthcare spending rises and awareness of lactose's role in drug delivery and infant nutrition grows, the sector presents sustained opportunities for suppliers focusing on purity compliance, customization, and application-specific innovations. Industry participants should monitor regulatory alignments and emerging therapies to optimize positioning in this resilient excipient category.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Pharmaceutical Grade Lactose Market Segmentation

  • By Product Type
  • B-lactose
  • a-Lactose monohydrate
  • Amorphous Lactose
  • Spray Dried Lactose
  • By Application
  • Tablets
  • Capsules
  • Dry Powder Inhalers (DPI)
  • Sachets
  • Parenteral Formulations (Bulking Agent)
  • Oral Suspensions
  • By End-User
  • Pharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Nutraceutical Manufacturers
  • Research & Development Laboratories
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PHARMACEUTICAL GRADE LACTOSE MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. B-lactose
  • 5.3. a-Lactose monohydrate
  • 5.4. Amorphous Lactose
  • 5.5. Spray Dried Lactose

6. PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Tablets
  • 6.3. Capsules
  • 6.4. Dry Powder Inhalers (DPI)
  • 6.5. Sachets
  • 6.6. Parenteral Formulations (Bulking Agent)
  • 6.7. Oral Suspensions

7. PHARMACEUTICAL GRADE LACTOSE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical Companies
  • 7.3. Contract Manufacturing Organizations (CMOs)
  • 7.4. Contract Development & Manufacturing Organizations (CDMOs)
  • 7.5. Nutraceutical Manufacturers
  • 7.6. Research & Development Laboratories

8. PHARMACEUTICAL GRADE LACTOSE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Indonesia
    • 8.6.7. Thailand
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Armor Proteines (Savencia Group)
  • 10.2. BASF Corporation
  • 10.3. Charotar Casein Company
  • 10.4. Fengchen Group Co., Ltd.
  • 10.5. Alpavit
  • 10.6. Kavya Pharma
  • 10.7. Lactose (India) Limited
  • 10.8. MEGGLE GmbH & Co. KG
  • 10.9. FrieslandCampina
  • 10.10. Surfachem Group Ltd. (2M Holdings).

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations